Good time to quietly load up before the story develops. Management, shares on issue, market cap, intended industry, development plan and cash on hand all tick the boxes for me.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%